Skip to content


BMC Proceedings

Open Access

Mastermind-like 1 (MAML-1) as a new metastatic marker in esophageal squamous cell carcinoma

  • Mohammad M Forghanifard1Email author,
  • Moein Farshchian2,
  • Reza Raeisossadati2,
  • Mohammad N Forghani3,
  • Meysam Moghbeli2,
  • Hussein Naseh4 and
  • Mohammad R Abbaszadegan2
BMC Proceedings20104(Suppl 2):P3

Published: 24 September 2010


Esophageal Squamous Cell CarcinomaNotch SignalingNotch Signaling PathwayDeath ProgramTumor Cell Type

Deregulation of the normal cellular processes that mediate cell proliferation, differentiation and death programs, have been seeing in various tumor cell types [1]. Notch signaling pathway that plays fundamental roles in definition of the cell fate and self-renewal is frequently deregulated in human malignancies, by up or down regulation, where it may act either as an oncogene or as a tumor suppressor depending on the cell context [2, 3]. The MAML proteins are transcriptional co-activators of notch signalling that are not only essential for related responses, but also have some regulatory functions in other signaling pathways, including p53 and Wnt/beta-catenin, and therefore have a central role in signaling cross talk of diverse cellular processes such as cell proliferation, differentiation and survival [4].

In current study, the expression of MAML-1 and EGFR genes were analyzed in 44 esophageal squamous cell carcinoma (ESCC) patients with the quantitative (real-time) RT-PCR. Overexpression of these genes was found in 45.5% and 38.6% of ESCC samples respectively. Relative expression of MAML-1 was significantly associated with the lymph node metastasis of tumor cells (P < 0.05).

Since MAML-1 is an essential transcription coactivator of notch signaling pathway and downstream related genes expression, we extrapolated that, notch signaling may contribute in tumor development and metastasis in ESCC, however further studies are required. We report for the first time that MAML-1 gene is overexpressed as a metastasis-related gene in ESCC samples. This indicates that MAML-1 may be a possible metastatic marker of ESCC and a possible good therapeutic target in order to block tumor cell metastasis.

Authors’ Affiliations

Department of Biological Science, Islamic Azad University, Damghan Branch, Damghan, Iran (Islamic Republic of)
Human Genetic Division, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran (Islamic Republic of)
Department of Surgery, Omid Hospital, MUMS, Mashhad, Iran (Islamic Republic of)
Department of Pathology, Omid Hospital, MUMS, Mashhad, Iran (Islamic Republic of)


  1. Allenspach EJ, Maillard I, Aster JC, Pear WS: Notch signaling in cancer. Cancer Biol Ther. 2002, 1: 466-476. 10.4161/cbt.1.5.162.View ArticlePubMedGoogle Scholar
  2. Koch U, Radtke F: Notch and cancer: a double-edged sword. Cell Mol Life Sci. 2007, 64: 2746-2762. 10.1007/s00018-007-7164-1.View ArticlePubMedGoogle Scholar
  3. Bolós V, Grego-Bessa J, de la Pompa JL: Notch signaling in development and cancer. Endocr Rev. 2007, 28: 339-363. 10.1210/er.2006-0046.View ArticlePubMedGoogle Scholar
  4. McElhinny AS, Li J-L, Wu L: Mastermind-like transcriptional co-activators: emerging roles in regulating cross talk among multiple signaling pathways. Oncogene. 2008, 27: 5138-5147. 10.1038/onc.2008.228.View ArticlePubMedGoogle Scholar


© Forghanifard et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.